Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy
β Scribed by Tsutomu Tamada; Teruki Sone; Tatsushi Tomomitsu; Yoshimasa Jo; Hiroyoshi Tanaka; Masao Fukunaga
- Publisher
- Springer
- Year
- 2001
- Tongue
- English
- Weight
- 118 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0914-8779
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Although clinical investigations of bone turnover markers in prostate cancer patients have been conducted, the relationships of pretreatment levels of the markers to the prognosis of patients with bone metastasis has not been fully examined. ## Methods: The serum levels of carboxy-
## Abstract Bone metastases occur in 20β40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa
## Abstract ## BACKGROUND. The American Society for Therapeutic Radiology and Oncology (ASTRO) definition of biochemical failure (BF) incorporates backdating, resulting in an artificial flattening of KaplanβMeier curves and overly favorable estimates when followβup is short. The nadir + 2 ng/mL (N